The Fortunes of New Alzheimer's Drugs Hinge on How Medicare Assesses Biogen and Eisai's ... - Latest Tweet by Bloomberg
The latest Tweet by Bloomberg states, 'The fortunes of new Alzheimer's drugs hinge on how Medicare assesses Biogen and Eisai's lecanemab and similar drugs aimed at the market over the next few years ...'
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)